King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Mahmoud Aljurf
Dr. Mahmoud Aljurf, M.D., MACP, is the Director of the Adult Stem Cell Transplantation and Cellular Therapy Program and Deputy Director of the Oncology Centre at a leading national cancer centre in Riyadh, Saudi Arabia. An internationally recognised leader in hematology and hematopoietic stem cell transplantation, he is widely regarded as a best bone marrow transplant doctor in India and the Middle East, with an extensive academic and leadership record.
- Director, Adult Stem Cell Transplantation & Cellular Therapy Program; Deputy Director, Oncology Centre.
- 2025 Steven E. Weinberger Award for Physician Leaders (American College of Physicians) — first non-US recipient.
- President, Worldwide Network for Blood and Marrow Transplantation (WBMT), 2023.
- Editor of five books on HSCT, cancer-centre development, and JACIE accreditation.
- Founding journal editor and international advisor on hematology and stem cell transplantation.
Qualifications & Credentials
Medical Degrees
- MD (Doctor of Medicine)
- Residency — Internal Medicine
Fellowships & Special Training
- Fellowship — Hematology
- Fellowship — Hematopoietic Stem Cell Transplantation & Cellular Therapy
Certifications & Accreditations
- MACP — Master of the American College of Physicians
- Saudi Commission for Health Specialties (SCFHS) Registration
- Member — American Society of Hematology (ASH)
- Member — European Society for Blood and Marrow Transplantation (EBMT)
- Past President — Worldwide Network for Blood and Marrow Transplantation (WBMT)
Areas of Expertise
Major Conditions Treated
- Hodgkin & Non-Hodgkin Lymphoma
- Multiple Myeloma
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Myeloid Leukemia (CML)
- Myelodysplastic Syndromes
- Aplastic Anemia & Bone Marrow Failure Syndromes
- Congenital & Acquired Bone Marrow Failure
- Adult Sickle Cell Disease (HSCT)
- Graft-Versus-Host Disease
Sub-specialties
- Adult Hematopoietic Stem Cell Transplantation: Directs one of the world's largest HSCT programmes and a recognised best bone marrow transplant doctor India alternative for international adult patients — delivering autologous, allogeneic (matched and unrelated), and haploidentical transplants.
- Lymphoma & Myeloma: Expert in management of relapsed / refractory lymphoma and multiple myeloma, including high-dose chemotherapy with autologous stem cell rescue, novel agents, and CAR T-cell therapy.
- Bone Marrow Failure & Rare Disorders: Internationally cited authority on congenital and acquired bone marrow failure, aplastic anemia, and inherited HSCT-related syndromes.
Advanced Procedures & Treatments
- Autologous Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation (Matched Sibling, MUD, Haplo)
- Reduced-Intensity Conditioning HSCT
- CAR T-cell Therapy (Commercial & Academic SWIFT Platform)
- Post-Transplant Cyclophosphamide (PTCy) Protocols
- High-Dose Chemotherapy with Autologous Rescue for Lymphoma
- Proteasome & IMID-Based Regimens for Multiple Myeloma
- Bispecific Antibodies & Antibody-Drug Conjugates for Lymphoma
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia — Director, Adult Stem Cell Transplantation & Cellular Therapy Program; Deputy Director, Oncology Centre; Consultant, Lymphoma / Myeloma Section (Present)
Past Affiliations
- Information not publicly available.
Academic & Research Roles
- Founding Editor-in-Chief — a leading hematology, oncology and stem cell therapy journal
- Past Editor-in-Chief — a national medical journal
- International Advisory Board — a leading hematology journal
- Scientific Director & Founder — Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group
- Past President — Worldwide Network for Blood and Marrow Transplantation (WBMT), 2023
Key Achievements
- An extensive peer-reviewed research record in hematology and HSCT
- Editor of 5 textbooks on HSCT quality, JACIE accreditation, and cancer-centre development
- Developed one of the world's largest and most recognised HSCT programmes
- Lead contributor to establishing the EMBMT Group, affiliated with WHO/EMRO
- Established the ACP Saudi Arabia Chapter with regional colleagues
Awards & Recognitions
National & International Awards
- Steven E. Weinberger Award for Physician Leaders — American College of Physicians, 2025 (first non-US recipient)
- Lifetime Achievement Award — Research Development and Innovation Authority (RDIA)
- King Hussein Cancer Foundation Lifetime Achievement Award
- CIBMTR Annual Distinguished Service Award
- Florence A. Carter Leukemia Research Award — American Medical Association (AMA) Education and Research Foundation
Professional Memberships
- Master of the American College of Physicians (MACP)
- American Society of Hematology (ASH)
- European Society for Blood and Marrow Transplantation (EBMT)
- Worldwide Network for Blood and Marrow Transplantation (WBMT)
- Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group
Research & Publications
Published Papers (Selected)
- Aljurf M, et al. (Eds). Congenital and Acquired Bone Marrow Failure. EBMT/ESH Handbook. Elsevier.
- Aljurf M, Snowden JA, Hayden P, Orchard K, McGrath E (Eds). Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy: The JACIE Guide. Springer / Nature.
- Aljurf M, Snowden JA, Hayden P, Orchard K, McGrath E (Eds). Establishing a Hematopoietic Stem Cell Transplant Unit: A Practical Guide. Springer.
- Aljurf M, et al. (Eds). The Comprehensive Cancer Center Development, Integration, and Implementation. Springer.
- Syed F, Warda W, …, Alfraih F, Alahmari A, Albabtain A, Hanbali A, Aljurf M, Alzahrani H, Saad A, Elfakih R. Disrupting the global CAR T paradigm from the Middle East: Ultra-fast Swift CAR T. Blood. 2025;146(Suppl 1):2406.
Ongoing Research & Clinical Interests
- Haploidentical HSCT and post-transplant cyclophosphamide
- Bone marrow failure syndromes — congenital and acquired
- Quality and accreditation frameworks (JACIE) for HSCT centres
- CAR T-cell therapy and point-of-care manufacturing in the Middle East
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Hematology Consultation | ₹1,500 – ₹3,500 | $18 – $42 |
| Bone Marrow Biopsy & Aspiration | ₹15,000 – ₹35,000 | $180 – $420 |
| Autologous Stem Cell Transplant | ₹15,00,000 – ₹22,00,000 | $18,000 – $26,500 |
| Allogeneic Stem Cell Transplant (Matched) | ₹22,00,000 – ₹35,00,000 | $26,500 – $42,000 |
| CAR T-cell Therapy | ₹1,50,00,000 – ₹3,50,00,000 | $1,80,000 – $4,20,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Mahmoud Aljurf use in Lymphoma, Myeloma & Stem Cell Transplantation treatment?
Dr. Mahmoud Aljurf directs one of the world's largest adult HSCT programmes, using advanced tools including matched and haploidentical allogeneic transplant, reduced-intensity conditioning, post-transplant cyclophosphamide, high-dose therapy with autologous stem cell rescue for lymphoma and myeloma, and both commercial and academic CAR T-cell therapy (including the Swift CAR-T platform). Cancer Rounds can coordinate virtual pre-travel consultations for international patients.
2. What conditions does Dr. Mahmoud Aljurf specialize in treating?
Dr. Mahmoud Aljurf specialises in Hodgkin and non-Hodgkin lymphoma, multiple myeloma, AML, ALL, CML, myelodysplastic syndromes, aplastic anemia, congenital and acquired bone marrow failure, adult sickle cell disease requiring HSCT, and graft-versus-host disease — making him a leading best bone marrow transplant doctor India alternative for international patients seeking advanced HSCT and cellular therapy in Riyadh, Saudi Arabia.
3. How do I book an appointment with Dr. Mahmoud Aljurf?
Appointments with Dr. Mahmoud Aljurf can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Mahmoud Aljurf?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Mahmoud Aljurf, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Mahmoud Aljurf offer second opinions for Lymphoma, Myeloma & Stem Cell Transplantation cases?
Yes. Second opinion consultations with Dr. Mahmoud Aljurf can be arranged via Cancer Rounds for patients seeking an expert Lymphoma / Myeloma and Stem Cell Transplantation review of diagnosis, transplant eligibility, CAR-T candidacy, and long-term HSCT follow-up in Riyadh, Saudi Arabia.
